Key facts
- It has raised $270K across 1 recorded rounds; the latest was Seed Round ($270K) in Sep 2025.
- REVO Oncology Diagnostics has filed 1 Form D with the SEC, most recently Apr 2026 ($270K sold to 7 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for REVO Oncology Diagnostics
Create free account
No card required
Funding rounds
1 roundsAbout REVO Oncology Diagnostics
The company is currently operating in Stealth mode.
- Sector
- Business Products and Services (B2B)
- HQ
- Frisco, TX, United States
- Founded
- 2025
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
REVO Oncology Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in REVO Oncology Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on REVO Oncology Diagnostics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.